Regenerative Medicine & Stem Cell Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Stem Cell Clinic Operators, Regenerative Medicine Physicians, Biologics Manufacturers, Exosome Product Companies, and Healthcare Executives Facing FDA Investigations, DOJ Prosecutions, and FTC Enforcement Actions.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends stem cell clinic operators, regenerative medicine physicians, orthopedic surgeons, dermatologists, anti-aging practitioners, biologics manufacturers, exosome product companies, HCT/P establishments, and healthcare executives in federal and state investigations and prosecutions involving the manufacture, marketing, and administration of unapproved stem cell therapies, exosome products, and other regenerative medicine treatments.
The FDA’s enforcement campaign against unapproved regenerative medicine therapies is one of the most sustained regulatory crackdowns in healthcare. Since 2018, the FDA has issued more than 400 warning letters to stem cell clinics and manufacturers. The Ninth Circuit and the Eleventh Circuit have both ruled that clinics offering stem cell procedures using stromal vascular fraction (SVF) derived from adipose tissue are subject to FDA regulation as drug manufacturers. DOJ has obtained criminal convictions against operators who continued distributing unapproved biological products after receiving FDA warning letters. The FTC has obtained permanent bans and monetary penalties against promoters of unsubstantiated regenerative medicine claims. The enforcement discretion period for HCT/P products ended in May 2021. Active prosecution is the current posture.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined experience at DOJ’s Fraud Section. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ involving over $2.8 billion in alleged false and fraudulent claims. DOJ’s Health and Safety Unit, created in November 2025, now handles criminal FDCA and biologics prosecutions within the Fraud Section. The firm defends individuals in the same enforcement actions that the Fraud Section now brings against regenerative medicine providers.
Armstrong & Bradylyons PLLC defends every regenerative medicine and stem cell enforcement matter from the start as if it will proceed to a criminal prosecution. FDA enforcement is escalating from warning letters to criminal referrals. The firm prepares accordingly.
Regenerative medicine enforcement follows the same FDA-to-DOJ pipeline as peptide and compounding pharmacy enforcement. The FDA issues warning letters, conducts inspections, and refers matters to DOJ for criminal prosecution. DOJ’s Health and Safety Unit prosecutes criminal FDCA violations. The FTC pursues separate enforcement for false advertising. State medical boards initiate licensing proceedings. The firm’s attorneys understand every stage of this pipeline from their years building healthcare fraud cases at DOJ.
Scott Armstrong served for nearly a decade at DOJ’s Fraud Section, where he tried 16 federal jury trials. Drew Bradylyons supervised the Healthcare Fraud Unit’s Miami Strike Force and served as Chief of EDVA’s Financial Crimes Unit. That combined experience provides the firm with an unmatched understanding of how the government investigates and prosecutes healthcare providers marketing unapproved treatments.
The federal enforcement campaign against unapproved regenerative medicine therapies involves coordinated action by the FDA, DOJ, the FTC, and state regulators. The enforcement has progressed from regulatory warnings to permanent injunctions and criminal convictions.
FDA Warning Letters and Injunctions
The FDA has issued more than 400 warning letters to stem cell clinics and manufacturers since December 2018. The FDA’s Center for Biologics Evaluation and Research (CBER) targets clinics marketing products that the FDA considers unapproved new drugs or unlicensed biological products. Warning letters cite distribution of unapproved biological products, failure to obtain a Biologics License Application (BLA) or Investigational New Drug (IND) application, violations of current Good Manufacturing Practice (cGMP) and current Good Tissue Practice (cGTP) requirements, and false or misleading therapeutic claims. The FDA has obtained permanent injunctions and consent decrees against clinics that continued operations after receiving warning letters.
Criminal Prosecutions
DOJ has obtained criminal convictions against operators who distributed unapproved biological products. In July 2024, a defendant pleaded guilty in the Central District of California to a felony FDCA charge for selling and distributing injectable stem cell products manufactured from human umbilical cord blood. The products were linked to 19 hospitalizations. The defendant had previously received two FDA warning letters and continued distributing the products. The Ninth Circuit’s September 2024 ruling in California Stem Cell Treatment Center v. FDA is expected to increase criminal prosecution of clinics that use SVF derived from adipose tissue, which both the Ninth and Eleventh Circuits now hold is subject to FDA regulation as a drug.
Exosome and Extracellular Vesicle Enforcement
The FDA treats exosome products as unapproved drugs and unlicensed biological products. There are zero FDA-approved exosome products for any medical use. The FDA has issued warning letters to firms distributing exosome products with therapeutic claims. The CDC has documented outbreaks linked to unapproved birth-derived injections. The FDA’s enforcement discretion period for HCT/P products ended in May 2021. Clinics that sell or administer exosome products for regenerative, cosmetic, or anti-aging purposes face FDA enforcement and DOJ criminal referral.
FTC Enforcement
The FTC has prosecuted clinics for unsubstantiated stem cell and regenerative medicine claims. In 2024 and 2025, the FTC obtained permanent bans and monetary penalties against promoters of unproven regenerative treatments. FTC enforcement targets deceptive advertising, false efficacy claims, and misleading testimonials. FTC actions are separate from FDA and DOJ enforcement and create additional civil liability.
Appellate Court Decisions Expanding FDA Authority
Two federal appellate courts have affirmed the FDA’s regulatory authority over stem cell therapies. The Eleventh Circuit affirmed in US Stem Cell Clinic that clinics offering unapproved stem cell treatments are subject to FDA regulation. The Ninth Circuit ruled in September 2024 that SVF created from adipose tissue via enzymatic digestion does not qualify for the same surgical procedure (SSP) exception and is subject to regulation as a drug. These rulings eliminate the primary legal defense that stem cell clinics had used to avoid FDA oversight. Clinics that continue offering treatments without FDA approval face significantly increased enforcement risk.
The firm’s defense practice is built on healthcare fraud trial experience, deep understanding of the FDA regulatory framework for biological products, and years of experience at DOJ’s Fraud Section. These tools are deployed at every phase of a case.
Responding to Warning Letters, Form 483s, and Criminal Referrals
The firm defends clinics and manufacturers responding to FDA warning letters, Form 483 inspection observations, consent decrees, and criminal referrals. An FDA warning letter is the first step in an enforcement pathway that can lead to permanent injunction or criminal prosecution. The firm develops response strategies designed to resolve regulatory matters and prevent escalation. Where FDA has already referred the matter to DOJ, the firm provides criminal defense from the outset.
Defending Against Allegations That Products Are Unapproved Drugs or Biologics
The central regulatory question is whether a clinic’s product qualifies as an HCT/P regulated under Section 361 of the Public Health Service Act or whether it is an unapproved drug or unlicensed biologic requiring a BLA or IND. The firm analyzes the product, processing methods, and clinical application against the FDA’s HCT/P regulatory framework, including the same surgical procedure exception, minimal manipulation criteria, and homologous use requirements under 21 C.F.R. Part 1271.
Defending Against DOJ Prosecution for Unapproved Drug and Biologics Distribution
When enforcement escalates to DOJ criminal prosecution, the charges include distribution of unapproved new drugs, distribution of unlicensed biological products, wire fraud, healthcare fraud, and conspiracy. The firm provides trial-ready criminal defense. The firm’s attorneys tried 25 federal jury trials in complex fraud cases. They know how federal prosecutors build and present these cases.
Defending Against FTC Enforcement for Deceptive Advertising Claims
The FTC enforces prohibitions against deceptive advertising of regenerative medicine products. The firm defends clinics and manufacturers against FTC investigations, civil investigative demands, consent orders, and litigation. The firm analyzes marketing claims, website content, patient testimonials, and social media advertising to identify exposure and develop a defense strategy that addresses both FTC and parallel FDA concerns.
Federal regenerative medicine enforcement targets every participant in the supply chain: from the manufacturers who produce biological products, to the clinics that administer treatments, the physicians who perform procedures, and the companies that market products online. Armstrong & Bradylyons PLLC defends these individuals in federal and state investigations and prosecutions.
Defense of Stem Cell Clinic Operators and Owners
The firm defends owners and operators of stem cell clinics, regenerative medicine centers, anti-aging clinics, and aesthetic medicine practices. Clinic operators face criminal exposure when the government alleges they administered unapproved biological products, made false therapeutic claims, continued operations after receiving FDA warning letters, or marketed treatments for conditions including Parkinson’s disease, ALS, COPD, arthritis, and macular degeneration without FDA approval. The firm defends clinic operators by analyzing regulatory classification, demonstrating compliance with HCT/P requirements, and challenging the government’s evidence of intent.
Defense of Physicians and Medical Professionals
The firm defends physicians, orthopedic surgeons, dermatologists, plastic surgeons, and other medical professionals who administer stem cell, PRP, exosome, or other regenerative medicine treatments. Physicians face exposure when the government alleges they administered unapproved products, compounded biological products in-house without authority, made therapeutic claims unsupported by clinical evidence, or billed Medicare or insurance for unapproved treatments. The firm defends physicians by establishing that clinical practices complied with applicable FDA and state law.
Defense of Biologics Manufacturers and HCT/P Establishments
The firm defends manufacturers of stem cell products, exosome products, umbilical cord-derived products, amniotic membrane products, and other HCT/P establishments. Manufacturers face criminal exposure for distributing unapproved biological products without a BLA, for cGMP and cGTP violations, for failure to register with the FDA, and for continuing distribution after receiving warning letters. The firm defends manufacturers through FDA inspections, warning letter responses, consent decree negotiations, and criminal proceedings.
Defense of Online Sellers and Marketing Companies
The firm defends companies and individuals who market regenerative medicine products online. Online sellers face FDA, FTC, and state attorney general enforcement for making therapeutic claims about unapproved products, marketing products with false or misleading advertising, and selling products intended for human use without FDA approval. The firm defends sellers by analyzing marketing practices, product claims, and regulatory classification.
Defense of Executives and Investors
The firm defends corporate executives, investors, and board members of regenerative medicine companies. Executives face personal criminal liability when the government alleges they directed distribution of unapproved products, approved marketing with false therapeutic claims, or continued operations in defiance of FDA enforcement. The firm defends executives by challenging the government’s evidence of personal knowledge, direction, and intent.
Regenerative medicine enforcement involves coordinated action by the FDA, DOJ, the FTC, and state regulators. Scott Armstrong and Drew Bradylyons understand how regulatory investigations become criminal referrals from their years at DOJ’s Fraud Section.
FDA Warning Letters and Inspection Findings
The FDA issues warning letters to clinics and manufacturers identifying violations of the FDCA and the Public Health Service Act. The FDA’s CBER conducts inspections of HCT/P establishments and issues Form 483 observations for cGMP, cGTP, donor screening, and aseptic practice violations. Warning letters and inspection findings are published on the FDA’s website. More than 400 warning letters have been issued since 2018.
FDA Criminal Referrals to DOJ
When the FDA determines that violations are willful or involve patient harm, it refers the matter to DOJ for criminal prosecution. DOJ’s Health and Safety Unit handles criminal FDCA and biologics prosecutions. Referrals target operators who distribute unapproved products after receiving warning letters, who cause patient injuries, or who engage in fraud.
FTC Investigations and Civil Enforcement
The FTC investigates deceptive advertising of regenerative medicine products. The FTC issues civil investigative demands, negotiates consent orders, and litigates for injunctive relief and monetary penalties. FTC enforcement is separate from FDA enforcement and creates independent liability.
Adverse Event Reports and Patient Harm Investigations
The FDA investigates adverse event reports associated with unapproved regenerative medicine therapies. The FDA has received reports of blindness, tumor formation, infections, and hospitalizations linked to unapproved stem cell and exosome products. Patient harm accelerates enforcement and increases the probability of criminal referral.
Medicare and Insurance Billing Analysis
HHS-OIG and CMS analyze claims data to identify providers billing Medicare or insurance for unapproved regenerative medicine treatments. Billing for unapproved products generates False Claims Act and healthcare fraud exposure.
State Medical Board and Attorney General Enforcement
State medical boards investigate physicians who administer unapproved treatments. State attorneys general enforce consumer protection statutes against clinics that make deceptive marketing claims. Florida has proposed legislation addressing stem cell therapy regulation. State proceedings run in parallel with federal enforcement.
Regenerative medicine prosecutions combine FDCA and biologics violations with traditional healthcare fraud statutes. The enforcement is multi-layered.
Distribution of Unapproved New Drugs (21 U.S.C. §§ 331, 333)
Section 331 prohibits introduction of unapproved new drugs into interstate commerce. Unapproved stem cell and exosome products are unapproved new drugs. Misdemeanor violations carry up to one year. Felony violations with intent to defraud carry up to three years under Section 333, or up to 10 years for second offenses or offenses involving death.
Distribution of Unlicensed Biological Products (42 U.S.C. § 262)
Section 262 of the Public Health Service Act requires a BLA for biological products. Distribution of an unlicensed biological product is a criminal offense. Stem cell products, exosome products, and other biologics that do not qualify for Section 361 HCT/P regulation require a BLA.
Wire Fraud (18 U.S.C. § 1343)
Wire fraud carries up to 20 years per count. DOJ uses wire fraud to escalate regenerative medicine cases beyond FDCA misdemeanors. Wire fraud captures online sales, marketing, electronic payment processing, and interstate communications.
Healthcare Fraud (18 U.S.C. § 1347)
Healthcare fraud is charged when clinics bill Medicare or insurance for unapproved treatments. Up to 10 years per count. If serious bodily injury results, up to 20 years.
False Claims Act (31 U.S.C. §§ 3729–3733)
The False Claims Act provides civil liability for billing federal programs for unapproved treatments. Qui tam whistleblower complaints drive FCA investigations in the regenerative medicine sector.
Seizure, Injunction, Forfeiture, and Collateral Consequences
The FDA can seek judicial seizure of adulterated or misbranded products and permanent injunctions against clinics. DOJ pursues forfeiture. State medical boards revoke licenses. State attorneys general seek consumer protection penalties. FDA warning letters create a permanent public record. For regenerative medicine providers, these consequences can permanently end a practice.
Are Stem Cell Treatments FDA-Approved?
The only FDA-approved stem cell-based therapies consist of blood-forming stem cells derived from cord blood, used to treat certain cancers and blood disorders. No stem cell treatment using SVF from adipose tissue, umbilical cord-derived products, or exosomes has been approved by the FDA for any therapeutic use. Clinics that administer unapproved stem cell treatments are distributing unapproved new drugs and unlicensed biological products. The FDA has issued more than 400 warning letters to clinics and manufacturers offering violative products.
What Is the Same Surgical Procedure Exception and Does It Protect Stem Cell Clinics?
The same surgical procedure (SSP) exception applies to HCT/Ps that are removed from a patient and implanted back into the same patient during the same surgical procedure. Both the Ninth Circuit and the Eleventh Circuit have ruled that stem cell treatments using SVF created from adipose tissue via enzymatic digestion do not qualify for the SSP exception. The courts held that the processing alters the tissue sufficiently that it constitutes an unapproved drug subject to FDA regulation. These rulings eliminate the primary legal defense that stem cell clinics had used to avoid FDA oversight.
Can an FDA Warning Letter Lead to Criminal Prosecution?
Yes. An FDA warning letter is a regulatory action, not a criminal charge. But continuing to distribute unapproved products after receiving a warning letter dramatically increases the risk of criminal referral. The defendant who pleaded guilty in July 2024 to distributing unapproved stem cell products had received two prior FDA warning letters. Defiance of an FDA warning letter is treated as evidence of willfulness and intent to defraud, which elevates an FDCA violation from a misdemeanor to a felony.
Are Exosome Products FDA-Approved?
No. There are zero FDA-approved exosome products for any medical use. The FDA treats exosome products as unapproved drugs and unlicensed biological products. Clinics that sell or administer exosome products for regenerative, cosmetic, or anti-aging purposes face FDA enforcement and potential DOJ criminal referral. The CDC has documented adverse events linked to unapproved birth-derived injectable products.
What Are the Criminal Penalties for Distributing Unapproved Stem Cell Products?
FDCA misdemeanor violations carry up to one year per count. Felony violations with intent to defraud carry up to three years, or up to 10 years for second offenses or offenses involving death. Wire fraud carries up to 20 years per count. Healthcare fraud carries up to 10 years per count. Distribution of unlicensed biological products violates the Public Health Service Act. Defendants also face seizure, injunction, forfeiture, and state licensing consequences.
What Is the Difference Between Section 361 HCT/Ps and Regulated Drugs or Biologics?
Under the FDA’s risk-based framework, HCT/Ps that meet specific criteria, including minimal manipulation and homologous use, are regulated under Section 361 of the Public Health Service Act. These products are subject to communicable disease regulations but do not require a BLA. HCT/Ps that do not meet these criteria are regulated as drugs or biologics, requiring FDA approval through a BLA or IND. The classification of a specific product under this framework determines whether its distribution is lawful or constitutes distribution of an unapproved drug.
Does the FTC Enforcement Create Separate Legal Risk?
Yes. The FTC enforces deceptive advertising prohibitions independently of the FDA and DOJ. FTC enforcement targets unsubstantiated therapeutic claims, misleading testimonials, and false efficacy representations. In 2024 and 2025, the FTC obtained permanent bans and monetary penalties against promoters of unproven regenerative treatments. FTC consent orders impose ongoing compliance obligations and can result in substantial financial penalties for violations.
Can Physicians Be Charged for Administering Stem Cell Treatments?
Yes. Physicians who administer unapproved stem cell or exosome products face exposure under the FDCA, the Public Health Service Act, and state medical practice acts. The FDA has stated that administering an unapproved biological product is not off-label use because the product has never been approved for any use. Physicians who compound biological products in-house without proper authority may be treated as unlicensed drug manufacturers. State medical boards initiate parallel disciplinary proceedings.
What Should a Clinic Do After Receiving an FDA Warning Letter?
A clinic that receives an FDA warning letter should engage experienced defense counsel immediately. The warning letter requires a written response within 15 business days outlining corrective actions. Continuing the violating conduct after receiving a warning letter dramatically increases criminal exposure. The firm develops a response strategy designed to resolve the regulatory matter, implement corrective measures, and prevent escalation to injunctive action or criminal referral.
Does Armstrong & Bradylyons Handle Regenerative Medicine Cases Nationwide?
Yes. Armstrong & Bradylyons PLLC defends individuals and companies in federal and state regenerative medicine and stem cell investigations in every jurisdiction. Enforcement is active nationwide, with significant cases in California, Florida, New Jersey, and Texas. The firm is based in Washington, D.C. and represents clients wherever the FDA, DOJ, the FTC, and state regulators bring enforcement actions against regenerative medicine providers.
Scott Armstrong and Drew Bradylyons have tried healthcare fraud cases and handled investigations in federal courts throughout the country during their combined 25-year DOJ career.